When does this change take effect?

This change is effective May 28, 2025.

Back to dashboard

CommercialCoverageMedium impact

08.02.28, Secukinumab (Cosentyx®) for Intravenous Use

Q: Who is affected by this change?

This affects Independence Blue Cross Rheumatology, Dermatology, Gastroenterology providers on Commercial plans.

Independence Blue Cross·Rheumatology, Dermatology, Gastroenterology·Pharmacy

Effective date

May 28, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

This policy update addresses Secukinumab (Cosentyx®) for intravenous use under commercial pharmacy policies. The reissued policy will take effect on May 28, 2025, but specific content changes are not detailed in the summary.

Action Required

Action needed

By May 28, 2025: Review the full policy document at the provided URL to understand specific changes to Secukinumab (Cosentyx®) intravenous use coverage. Update prior authorization requirements, billing procedures, and provider documentation as specified in the complete policy. Monitor for additional details as the effective date approaches.

Related policy hubs

Independence Blue Cross policies Rheumatology Dermatology Gastroenterology